Arqit Quantum Inc vs Medpace Holdings Inc — how do they compare? Arqit Quantum Inc trades at $23.52 (market cap $424.79M), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 39.8× Arqit Quantum Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | MEDP | |
|---|---|---|
Market Cap | $424.79M | $16.90B |
Sector | Technology | Technology |
52-Week High | $58.27 | $620.59 |
52-Week Low | $11.78 | $393.42 |
Enterprise Value | $398.10M | $16.52B |
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $23.70, up 4.82% today, with a bullish technical signal from moving averages and ADX. The stock shows extreme valuation metrics with a P/S of 352.9 and P/B of 14.9, while fundamentals reveal severe losses: Q1 2026 EPS missed at -$1.99, net income margin is -4,508.1%, and revenue remains minimal at $530K for 2025. Recent news highlights a proof of concept with nLighten and 829% YoY revenue growth in H1 FY26, signaling potential commercial traction in quantum-safe encryption.
Outlook hinges on scaling revenue to justify valuation, with risks from persistent cash burn and high SG&A. Analyst sentiment is split 50/50 buy/hold, reflecting optimism for government/telecom contracts against financial distress. The stock faces volatility near resistance at $25, requiring sustained growth to support bullish momentum.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →